First Time Loading...

Tango Therapeutics Inc
NASDAQ:TNGX

Watchlist Manager
Tango Therapeutics Inc Logo
Tango Therapeutics Inc
NASDAQ:TNGX
Watchlist
Price: 7.6 USD 3.97% Market Closed
Updated: May 15, 2024

Intrinsic Value

TNGX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Tango Therapeutics, Inc. operates as a biotechnology company that engages in discovering and delivering precision cancer medicines. [ Read More ]

The intrinsic value of one TNGX stock under the Base Case scenario is 3.5 USD. Compared to the current market price of 7.6 USD, Tango Therapeutics Inc is Overvalued by 54%.

Key Points:
TNGX Intrinsic Value
Base Case
3.5 USD
Overvaluation 54%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Tango Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling TNGX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Tango Therapeutics Inc

Provide an overview of the primary business activities
of Tango Therapeutics Inc.

What unique competitive advantages
does Tango Therapeutics Inc hold over its rivals?

What risks and challenges
does Tango Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Tango Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Tango Therapeutics Inc.

Provide P/S
for Tango Therapeutics Inc.

Provide P/E
for Tango Therapeutics Inc.

Provide P/OCF
for Tango Therapeutics Inc.

Provide P/FCFE
for Tango Therapeutics Inc.

Provide P/B
for Tango Therapeutics Inc.

Provide EV/S
for Tango Therapeutics Inc.

Provide EV/GP
for Tango Therapeutics Inc.

Provide EV/EBITDA
for Tango Therapeutics Inc.

Provide EV/EBIT
for Tango Therapeutics Inc.

Provide EV/OCF
for Tango Therapeutics Inc.

Provide EV/FCFF
for Tango Therapeutics Inc.

Provide EV/IC
for Tango Therapeutics Inc.

Show me price targets
for Tango Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Tango Therapeutics Inc?

How accurate were the past Revenue estimates
for Tango Therapeutics Inc?

What are the Net Income projections
for Tango Therapeutics Inc?

How accurate were the past Net Income estimates
for Tango Therapeutics Inc?

What are the EPS projections
for Tango Therapeutics Inc?

How accurate were the past EPS estimates
for Tango Therapeutics Inc?

What are the EBIT projections
for Tango Therapeutics Inc?

How accurate were the past EBIT estimates
for Tango Therapeutics Inc?

Compare the revenue forecasts
for Tango Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Tango Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Tango Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Tango Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Tango Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Tango Therapeutics Inc with its peers.

Analyze the financial leverage
of Tango Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Tango Therapeutics Inc.

Provide ROE
for Tango Therapeutics Inc.

Provide ROA
for Tango Therapeutics Inc.

Provide ROIC
for Tango Therapeutics Inc.

Provide ROCE
for Tango Therapeutics Inc.

Provide Gross Margin
for Tango Therapeutics Inc.

Provide Operating Margin
for Tango Therapeutics Inc.

Provide Net Margin
for Tango Therapeutics Inc.

Provide FCF Margin
for Tango Therapeutics Inc.

Show all solvency ratios
for Tango Therapeutics Inc.

Provide D/E Ratio
for Tango Therapeutics Inc.

Provide D/A Ratio
for Tango Therapeutics Inc.

Provide Interest Coverage Ratio
for Tango Therapeutics Inc.

Provide Altman Z-Score Ratio
for Tango Therapeutics Inc.

Provide Quick Ratio
for Tango Therapeutics Inc.

Provide Current Ratio
for Tango Therapeutics Inc.

Provide Cash Ratio
for Tango Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Tango Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Tango Therapeutics Inc?

What is the current Free Cash Flow
of Tango Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Tango Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Tango Therapeutics Inc

Current Assets 352m
Cash & Short-Term Investments 343.6m
Other Current Assets 8.4m
Non-Current Assets 54.2m
PP&E 51.6m
Other Non-Current Assets 2.6m
Current Liabilities 42.8m
Accounts Payable 3.9m
Accrued Liabilities 15.8m
Other Current Liabilities 23.1m
Non-Current Liabilities 99m
Other Non-Current Liabilities 99m
Efficiency

Earnings Waterfall
Tango Therapeutics Inc

Revenue
37.2m USD
Operating Expenses
-163.4m USD
Operating Income
-126.1m USD
Other Expenses
14.5m USD
Net Income
-111.6m USD

Free Cash Flow Analysis
Tango Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

TNGX Profitability Score
Profitability Due Diligence

Tango Therapeutics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

Exceptional 1-Year Revenue Growth
Negative Revenue Growth Forecast
Negative Operating Income
Negative Net Income
20/100
Profitability
Score

Tango Therapeutics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

TNGX Solvency Score
Solvency Due Diligence

Tango Therapeutics Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
62/100
Solvency
Score

Tango Therapeutics Inc's solvency score is 62/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TNGX Price Targets Summary
Tango Therapeutics Inc

Wall Street analysts forecast TNGX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TNGX is 17.92 USD with a low forecast of 16.16 USD and a high forecast of 21 USD.

Lowest
Price Target
16.16 USD
113% Upside
Average
Price Target
17.92 USD
136% Upside
Highest
Price Target
21 USD
176% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

TNGX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

TNGX Price
Tango Therapeutics Inc

1M 1M
+4%
6M 6M
+5%
1Y 1Y
+102%
3Y 3Y
-25%
5Y 5Y
-25%
10Y 10Y
-25%
Annual Price Range
7.6
52w Low
2.67
52w High
12.88
Price Metrics
Average Annual Return -12.97%
Standard Deviation of Annual Returns 28.59%
Max Drawdown -85%
Shares Statistics
Market Capitalization 811.2m USD
Shares Outstanding 106 735 000
Percentage of Shares Shorted 18.89%

TNGX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Tango Therapeutics Inc Logo
Tango Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

811.2m USD

Dividend Yield

0%

Description

Tango Therapeutics, Inc. operates as a biotechnology company that engages in discovering and delivering precision cancer medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 91 full-time employees. The company went IPO on 2020-09-03. The firm is engaged in the discovery and development of drugs at tumor suppressor gene loss in patients with unmet medical need. The Company’s product candidates include TNG908 and ubiquitin-specific protease 1 (USP1). Its TNG908, is a potent, selective, synthetic lethal, small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5), which is designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. The MTAP-deletion occurs in all human tumors, including cancers with unmet need, such as squamous cell lung, esophageal and bladder cancer. The Company’s USP1, is a synthetic lethal that target for BRCA1-mutant breast, ovarian and prostate cancer. The USP1 treats a patient population for poly (ADP-ribose) polymerase (PARP) inhibitors that are operative against cancers with BRCA1 and BRCA2 mutations.

Contact

MASSACHUSETTS
Cambridge
100 Binney St, Suite 700
+18573204900.0
https://www.tangotx.com/

IPO

2020-09-03

Employees

91

Officers

President, CEO & Director
Dr. Barbara L. Weber M.D.
Chief Financial Officer
Ms. Daniella Beckman CPA
Founder
Dr. Timothy K. Lu M.D., Ph.D.
Founder & Member of Scientific Advisory Board
Dr. Antoni Ribas M.D., Ph.D.
Chief Scientific Officer
Mr. Jannik N. Andersen Ph.D.
Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
Mr. Douglas J. Barry Esq., J.D.
Show More
Vice President of Human Resources
Mr. John C. Ross M.S.
Show Less

See Also

Discover More
What is the Intrinsic Value of one TNGX stock?

The intrinsic value of one TNGX stock under the Base Case scenario is 3.5 USD.

Is TNGX stock undervalued or overvalued?

Compared to the current market price of 7.6 USD, Tango Therapeutics Inc is Overvalued by 54%.